中國同輻(01763.HK):控股股東無償劃轉股權完成過户登記
格隆匯12月27日丨中國同輻(01763.HK)發佈公吿,有關(其中包括)中國核工業集團有限公司(“中核集團”)擬將其持有的全部約1.07億股公司內資股(約佔公司截至該公吿日期全部已發行股本總額的33.35%)無償劃轉予中國寶原投資有限公司(“中國寶原”)。公司於2023年12月26日接獲中國寶原轉發的中國證券登記結算有限責任公司出具的《過户登記確認書》,確認上述無償劃轉的相關股份的過户登記手續已辦理完畢。上述無償劃轉完成後,中國寶原已成為公司的直接控股股東,而中核集團仍為公司的最終控股股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.